Olanzapine: 5 agencies, 1998–2020
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 21.2 years separate the first record, 12 Nov 1998 at PHARMAC (New Zealand), from the most recent, 5 Feb 2020 at HAS (France).
TLV (Sweden) changed its position: not recommended on 29 Mar 2010, recommended by 29 Mar 2010, after a resubmission.
No assessment is on file from PBAC (Australia), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Nothing has been added since 2020; on this evidence the file is dormant.
4 distinct indication wordings are recorded for olanzapine by the agencies that label one in English (AWMSG and SMC).
PHARMAC (New Zealand) was first to assess olanzapine, on 12 Nov 1998; AWMSG (Wales) did not open a file until 27 Jul 2016 — an unusually long tail of 17.7 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 10 years in total.
4 of the 5 agencies here assessed olanzapine more than once, HAS (France) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed olanzapine.
The full ledger for olanzapine reads 12 recommended, 1 restricted, 1 not recommended and 1 other.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 5 Feb 2020 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| AWMSG (Wales) | 27 Jul 2016 | Maintenance treatment of adult patients with schizophrenia sufficiently stabilised during acute treatment with oral olan… | recommended with restrictions (resubmission) | source |
| TLV (Sweden) | 29 Mar 2010 | Vi beslutar att Zypadhera inte ska ingå i högkostnadsskyddet | rejection or exclusion | source |
| PHARMAC (New Zealand) | 1 Feb 2004 | Second line treatment of acute manic or mixed episodes in bipolar disorder | PTAC advice: Medium · decision reached | source |
| SMC (Scotland) | 6 Jun 2003 | Moderate to severe manic episodes | unknown | source |
10 further decisions for olanzapine, across 4 agencies, are not shown here. They link to 10 further source documents.
Related molecules
- aripiprazole — same ATC class N05A — Psycholeptics
- risperidone — same ATC class N05A — Psycholeptics
- paliperidone — same ATC class N05A — Psycholeptics
- quetiapine — same ATC class N05A — Psycholeptics
- lurasidone — same ATC class N05A — Psycholeptics
- droperidol — same ATC class N05A — Psycholeptics
Coverage: 15 decisions for olanzapine from 5 agencies, 1998 to 2020. Data to 7 Sep 2026. ATC class N05A — Psycholeptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.